Alexina J Mason

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1110082/publications.pdf

Version: 2024-02-01

567281 434195 33 1,726 15 31 citations h-index g-index papers 34 34 34 2231 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Design and analysis features used in small population and rare disease trials: A targeted review. Journal of Clinical Epidemiology, 2022, 144, 93-101.	5.0	6
2	A Scoping Review of Item-Level Missing Data in Within-Trial Cost-Effectiveness Analysis. Value in Health, 2022, , .	0.3	2
3	Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT. Health Technology Assessment, 2021, 25, 1-90.	2.8	4
4	Joint Longitudinal Models for Dealing With Missing at Random Data in Trial-Based Economic Evaluations. Value in Health, 2021, 24, 699-706.	0.3	6
5	Flexible Bayesian longitudinal models for costâ€effectiveness analyses with informative missing data. Health Economics (United Kingdom), 2021, 30, 3138-3158.	1.7	2
6	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and health economic analysis plan for the 65 trial in article. Journal of the Intensive Care Society, 2020, 21, 230-231.	2.2	2
7	A framework for extending trial design to facilitate missing data sensitivity analyses. BMC Medical Research Methodology, 2020, 20, 66.	3.1	7
8	A flexible hierarchical framework for improving inference in areaâ€referenced environmental health studies. Biometrical Journal, 2020, 62, 1650-1669.	1.0	2
9	Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension. JAMA - Journal of the American Medical Association, 2020, 323, 938.	7.4	169
10	The impact of resuscitation system factors on in-hospital cardiac arrest outcomes across UK hospitals: An observational study. Resuscitation, 2020, 151, 166-172.	3.0	3
11	Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Medicine, 2019, 45, 1392-1400.	8.2	33
12	Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Medicine, 2019, 45, 844-855.	8.2	97
13	Permissive versus restrictive temperature thresholds in critically ill children with fever and infection: a multicentre randomized clinical pilot trial. Critical Care, 2019, 23, 69.	5.8	18
14	Effect of a Nurse-Led Preventive Psychological Intervention on Symptoms of Posttraumatic Stress Disorder Among Critically Ill Patients. JAMA - Journal of the American Medical Association, 2019, 321, 665.	7.4	76
15	A full Bayesian model to handle structural ones and missingness in economic evaluations from individualâ€level data. Statistics in Medicine, 2019, 38, 1399-1420.	1.6	17
16	Different temperature thresholds for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility RCT. Health Technology Assessment, 2019, 23, 1-148.	2.8	6
17	Are large randomised controlled trials in severe sepsis and septic shock statistically disadvantaged by repeated inadvertent underestimates of required sample size?. BMJ Open, 2018, 8, e020068.	1.9	12
18	A Bayesian framework for health economic evaluation in studies with missing data. Health Economics (United Kingdom), 2018, 27, 1670-1683.	1.7	14

#	Article	lF	Citations
19	Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Efficacy and Mechanism Evaluation, 2018, 5, 1-94.	0.7	3
20	Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. Statistics in Medicine, 2017, 36, 754-771.	1.6	9
21	Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations. PharmacoEconomics - Open, 2017, 1, 79-97.	1.8	40
22	Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: Application to the IMPROVE trial. Clinical Trials, 2017, 14, 357-367.	1.6	33
23	Rejoinder. Clinical Trials, 2017, 14, 370-371.	1.6	0
24	Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. New England Journal of Medicine, 2016, 375, 1638-1648.	27.0	271
25	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2016, 316, 509.	7.4	456
26	Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJ Open, 2014, 4, e005866-e005866.	1.9	24
27	The Interaction of Vasopressin and Corticosteroids in Septic Shock. Critical Care Medicine, 2014, 42, 1325-1333.	0.9	106
28	An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials, 2014, 15, 199.	1.6	36
29	Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation, 2014, 124, 3667-3677.	8.2	140
30	Two-pronged Strategy for Using DIC to Compare Selection Models with Non-Ignorable Missing Responses. Bayesian Analysis, 2012, 7, .	3.0	15
31	Adjusting for Selection Effects in Epidemiologic Studies. Epidemiology, 2011, 22, 36-39.	2.7	41
32	Long lead-time forecasting of UK air passengers by Holt–Winters methods with damped trend. International Journal of Forecasting, 2001, 17, 71-82.	6.5	74
33	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and Health Economic Analysis Plan for the 65 trial. Journal of the Intensive Care Society, 0, , 175114371986038.	2.2	2